1 , laboratory of virology, medical school, university of crete, 71110 heraklion, crete, greece

Download 1 , Laboratory of Virology, Medical School, University of Crete, 71110 Heraklion, Crete, Greece

If you can't read please download the document

Post on 02-Feb-2016

33 views

Category:

Documents

0 download

Embed Size (px)

DESCRIPTION

MiR-21 can be used as independent prognostic factor for survival and metastasis in urinary bladder cancer. Apostolos Zaravinos 1 , Jelena Radojicic 3 , George I. Lambrou 2 , Dimitrios Volanis 1, 4 , Ioannis Boulalas 1, 4 , Dimitris Delakas 4 , Demetrios A. Spandidos 1. - PowerPoint PPT Presentation

TRANSCRIPT

  • 1, Laboratory of Virology, Medical School, University of Crete, 71110 Heraklion, Crete, Greece.2, 1st Department of Pediatrics, Choremeio Research Laboratory, University of Athens, 11527 Athens, Greece.3, Department of Surgical Pathology, Medical Faculty, University of Crete, 71110 Heraklion, Crete, Greece.4, Department of Urology, Asklipieio General Hospital, 16673 Voula, Athens, Greece.Table 1. Univariate logistic regression was utilized to assess the potential prognostic factors in overall survival, tumour recurrence and metastasis. Table 2. Multivariate logistic regression was utilized to assess the potential prognostic factors in overall survival, tumour recurrence and metastasis. Table 1. Table 2. Table 2. Spearmans rank correlation coefficient among microRNA, FGF2, OPN and VEGFA expression levels in urinary bladder cancer and adjacent normal tissue samples.

    VariableRelative risk95% Confidence IntervalP value

    Overall SurvivalmiR-10b0.7360.265-2.0480.558miR-19a0.6000.213-1.6890.333miR-19b0.6000.213-1.6890.333miR-210.2420.077-0.7580.015miR-126_10.6000.213-1.6890.333miR-145_10.4520.157-1.2990.140miR-205_10.7360.265-2.0480.558miR-2100.3350.113-0.9960.049miR-2210.4210.146-1.2110.108miR-296-5p0.6000.213-1.6890.333miR-378-11.2660.455-3.5200.651FGF20.4210.146-1.2110.108OPN1.1800.424-3.2810.751VEGFA1.4570.524-4.0560.471

    RecurrencemiR-10b0.7940.310-2.0370.632miR-19a0.7500.291-1.9310.551miR-19b1.1900.465-3.0500.716miR-210.6300.244-1.6240.339miR-126_10.9450.369-2.4240.907miR-145_11.7330.671-4.4760.256miR-205_11.0000.391-2.5591.000miR-2100.8670.338-2.2210.766miR-2210.9170.358-2.3460.856miR-296-5p0.6880.267-1.7710.438miR-378-12.0090.772-5.2290.153FGF20.5440.209-1.4120.211OPN1.0580.413-2.7120.907VEGFA0.5930.229-1.5400.283

    MetastasismiR-10b0.9660.349-2.6740.946miR-19a1.0360.374-2.8690.946miR-19b1.0360.374-2.8690.946miR-210.3350.113-0.9960.049miR-126_11.0360.374-2.8690.946miR-145_10.6000.213-1.6890.333miR-205_10.7360.265-2.0480.558miR-2100.7900.284-2.1960.651miR-2210.7360.265-2.0480.558miR-296-5p0.6000.213-1.6890.333miR-378-10.9660.349-2.6740.946FGF20.5590.199-1.5750.271OPN0.9000.325-2.4940.839VEGFA0.6440.229-1.8110.404

    VariableRelative risk95% Confidence IntervalP value

    Overall SurvivalmiR-210.1190.027-0.5270.005miR-2100.2300.060-0.8880.033miR-378_17.3161.544-34.6610.012

    RecurrencemiR-19a0.0000.000-1.0000.999miR-19b2.1E+090.000-1.0000.999miR-210.2050.049-0.8560.030miR-378_15.9841.176-30.4470.031

    MetastasismiR-210.3350.113-0.9960.049

    *

View more